Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Disease area: Airway diseases, Respiratory infections

Abstract

Background. Effect of inhaled glucocorticosteroids (IGCC) on the course of the disease and quality of life in patients with bronchiectasis in remission, has not yet been studied.Aim. Investigate the efficacy of combined inhaled drugs (IGCC + long-acting beta2-agonist) on quality of life, microbiological and functional parameters in patients with mixed bronchiectasis in remission.Methods. A 6-month study in 45 patients was researched. Mixed bronchiectasis verified by high resolution CT scan of the chest. Depending on the dose of inhaled corticosteroids patients were randomized: fluticasone propionate 250 mcg twice daily and 500 mcg twice daily. Quality of life was assessed by St. George's Respiratory Questionnaire. In the group treated with fluticasone propionate 1,000 mcg per day, after one month significantly decreased dyspnea, sputum production, cough frequency and the need for the use of short-acting beta2-agonists, but not observed changes in lung function: forced expiratory volume in 1 second, Gensler index, and microbiological profile of sputum (Staphylococcus aureus, Pseudomonas aureginosa).Results. In this group of patients was significantly improved quality of life (p <0.001) within three months of treatment. Community-acquired pneumonia is not registered.Conclusions. Application twice a day for 500 mcg fluticasone propionate in combination with long-acting beta2-agonist controls symptoms after the first month of treatment in patients with mixed bronchiectasis in remission. This result is confirmed by significant improvement of life quality.


Rating:

Share or cite this content

Citations should be made in the following way:
Eduard Khodosh (Kharkiv, Ukraine), Eduard Khodosh, Peter Poteiko, Valeriy Krutko, Dmitriy Khoroshun. Influence of inhaled glucocorticosteroids on course of the bronchiectasis. Eur Respir J 2015; 46: Suppl. 59, 2963

Member's Comments

No comment yet.

Related content which might interest you: Effects of prophylactic clarithromycin administration on quality of life in non-CF bronchiectasis patients Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 The use of home intravenous antibiotics in adult non-CF bronchiectasis Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Effect of long term azithromycin on exacerbations in non CF bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Effect of oral corticosteroids on symptomatic reflux in severe allergic asthma: Is there a link? Source: International Congress 2014 – The assessment of comorbidities Year: 2014 Chronic inhaled corticosteroids in patients with bronchiectasis who suffer an exacerbation Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Effects of beta-blockers on lung function in bronchial asthma patients Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease? Year: 2014 Effects of inhaled salmeterol/fluticasone on lung function in patients with bronchiectasis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Predictors of exacerbations in patients with bronchiectasis Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Effect of a 10-day oral corticosteroid course on hemostasis and inflammation in patients with stable asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Duration of inhaled corticosteroid therapy in children with asthma and frequency of community-acquired pneumonia in them Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Evaluation of Asthma control and oral corticosteroids in Severe Asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Adherence with inhaled corticosteroids in asthma: Does pregnancy lead to improved adherence? Source: International Congress 2014 – Asthma: still a heterogeneous condition! Year: 2014 Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes Source: International Congress 2016 – Airway stenting and ablation Year: 2016 Induced sputum in children With persistent asthma: The effect to inhaled corticosteroid treatment Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013 Health related quality of life in asthmatic subjects after 3 months treatment with inhaled corticosteroids Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Asthma comorbidities, a place for pulmonary embolism Source: Annual Congress 2013 –Asthma Year: 2013 Validation of a visual analogue score (LRTI-VAS) in non-CF bronchiectasis Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Microbiome Use to Stratify Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (MUSIC) trial: baseline data and impact of inhaled corticosteroid withdrawal in severe COPD with frequent exacerbations Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Dysphonia in asthmatic women using inhaled corticosteroids: It is not only a laryngeal inflammation Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Impact of bronchiectasis on the course of COPD Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016